Literature DB >> 8995588

Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers.

J M Navenot1, M Villanova, B Lucas-Héron, A Malandrini, D Blanchard, J P Louboutin.   

Abstract

Control of complement deposition on autologous cells is mediated by a group of complement regulatory membrane proteins acting at different levels of the complement cascade. Decay accelerating factor (CD55) prevents the assembly of C3 convertases and CD59 membrane inhibitor of reactive lysis (MIRL) restricts homologous complement lysis by the membrane attack complex of complement (MAC) by inhibition of C5b-8 catalyzed insertion of C9. The aim of this work was to study the eventual expression of CD55 and CD59 on human skeletal muscle fibers. Highly sensitive immunoblotting using murine monoclonal antibodies showed that CD59, but not CD55, was present in skeletal muscle fibers. Immunocytochemistry with a monoclonal antibody against CD59 demonstrated a dense granular immunostaining mainly localized at the level of the sarcolemma. Thus, CD59, but not CD55, is expressed on normal skeletal muscle fibers. CD59 may play a prominent role in preventing MAC deposition and subsequent complement-mediated damage in myopathies where the complement system activation is involved.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995588     DOI: 10.1002/(sici)1097-4598(199701)20:1<92::aid-mus12>3.0.co;2-3

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

1.  Extraocular muscle is defined by a fundamentally distinct gene expression profile.

Authors:  J D Porter; S Khanna; H J Kaminski; J S Rao; A P Merriam; C R Richmonds; P Leahy; J Li; F H Andrade
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

3.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 4.  Association of Blood Group Antigen CD59 with Disease.

Authors:  Christof Weinstock
Journal:  Transfus Med Hemother       Date:  2022-01-13       Impact factor: 3.747

Review 5.  The emerging role of complement in neuromuscular disorders.

Authors:  John D Lee; Trent M Woodruff
Journal:  Semin Immunopathol       Date:  2021-10-27       Impact factor: 9.623

Review 6.  The role of complement in experimental autoimmune myasthenia gravis.

Authors:  Linda L Kusner; Henry J Kaminski
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

7.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

8.  Isoform-specific expression of the Coxsackie and adenovirus receptor (CAR) in neuromuscular junction and cardiac intercalated discs.

Authors:  Christian A Shaw; Paul C Holland; Michael Sinnreich; Carol Allen; Kerstin Sollerbrant; George Karpati; Josephine Nalbantoglu
Journal:  BMC Cell Biol       Date:  2004-11-08       Impact factor: 4.241

Review 9.  Complement Inhibitor Therapy for Myasthenia Gravis.

Authors:  Khaled Albazli; Henry J Kaminski; James F Howard
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

Review 10.  Complement Inhibition for the Treatment of Myasthenia Gravis.

Authors:  Renato Mantegazza; Fiammetta Vanoli; Rita Frangiamore; Paola Cavalcante
Journal:  Immunotargets Ther       Date:  2020-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.